A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis
Latest Information Update: 08 Jul 2025
At a glance
- Drugs Nebokitug (Primary)
- Indications Primary sclerosing cholangitis
- Focus Proof of concept; Therapeutic Use
- Acronyms SPRING
- Sponsors Chemomab Therapeutics
Most Recent Events
- 30 Jun 2025 According to a Chemomab Therapeutics media release, rececent findings from this Phase 2 SPRING trial suggest that nebokitug may have disease-modifying potential in PSC and support advancement to a Phase 3 registration trial.
- 30 Jun 2025 Results published in the Media Release
- 30 Jun 2025 According to a Chemomab Therapeutics media release, company announced that data from the company's Phase 2 SPRING trial of nebokitug (CM-101) in patients with primary sclerosing cholangitis (PSC) was presented in an oral session1 at BSG Live 25, the annual scientific meeting of the British Society for Gastroenterology, in Glasgow, UK.